PYROVALERONE

- Everything we could find out about it

Home ] [ Controlled Substances ] [ Stimulants ]

Created Jan 2021

PYROVALERONE

  • [CENTROTON]
  • [THYMERGIX]
  • [VALEROPHENONE]

4-Methyl-beta-keto-prolintane
O-2371

DEA CODE 1485: Schedule 5

  • Pyrovalerone is a psychostimulant.
  • It has a central action.
  • Pyrovalerone inhibits the dopamine transporter and the norepinephrine transporter, and is a weak inhibitor of the serotonin transporter.
  • Pyrovalerone was demonstrated to reduce symptoms of chronic fatigue in humans.
  • It stimulated locomotor activity in mice.
  • Though pyrovalerone is still occasionally prescribed, it is used infrequently due to problems with abuse and dependence.
  • Side effects of pyrovalerone include anxiety, fragmented sleep or insomnia and trembling, shaking or muscle tremors.

SWGDRUG Pyrovalerone Monograph

CaymanChem PDF Pyrovalerone

  • A psychoactive drug
  • Stimulant effects
  • Used for the clinical treatment of chronic fatigue or lethargy and as an anorectic or appetite suppressant for weight loss purposes

    It was developed in the late 1960s and has since been used in France and several other European countries, and although pyrovalerone is still occasionally prescribed, it is used infrequently due to problems with abuse and dependence.

  • It is closely related on a structural level to a number of other stimulants
  • Side effects of pyrovalerone include anorexia or loss of appetite, anxiety, fragmented sleep or insomnia, and trembling, shaking, or muscle tremors.

Withdrawal following abuse upon discontinuation often results in depression

  
“Bath Salts” Intoxication - MDPV is structurally related to pyrovalerone and α-pyrrolidinophenone ... monitoring in the intensive care unit; second, routine drug screens do not detect PABS; third, PABS can be cut with ...
Wednesday January 31, 2024 - nejm.org

  
Stimulants | Link to this page

Home ] [ Controlled Substances ] [ Sources ]


· Controlled Substances
· Stimulants
· Pyrovalerone